Review
Antiangiogenic Agents and the Skin: Cutaneous Adverse Effects of Sorafenib, Sunitinib, and Bevacizumab
Fármacos antiangiogénicos y piel: efectos cutáneos adversos de sorafenib, sunitinib y bevacizumab
Servicio de Dermatología, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
Read
16927
Timeswas read the article
3800
Total PDF
13127
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 6 | 117 | 12 | 129 |
| 2025 5 | 377 | 33 | 410 |
| 2025 4 | 472 | 22 | 494 |
| 2025 3 | 356 | 28 | 384 |
| 2025 2 | 471 | 28 | 499 |
| 2025 1 | 308 | 33 | 341 |
| 2024 12 | 395 | 39 | 434 |
| 2024 11 | 258 | 69 | 327 |
| 2024 10 | 205 | 59 | 264 |
| 2024 9 | 248 | 29 | 277 |
| 2024 8 | 293 | 86 | 379 |
| 2024 7 | 273 | 41 | 314 |
| 2024 6 | 251 | 44 | 295 |
| 2024 5 | 227 | 55 | 282 |
| 2024 4 | 167 | 29 | 196 |
| 2024 3 | 210 | 34 | 244 |
| 2024 2 | 211 | 41 | 252 |
| 2024 1 | 219 | 42 | 261 |
| 2023 12 | 250 | 86 | 336 |
| 2023 11 | 267 | 49 | 316 |
| 2023 10 | 177 | 27 | 204 |
| 2023 9 | 180 | 40 | 220 |
| 2023 8 | 144 | 30 | 174 |
| 2023 7 | 159 | 53 | 212 |
| 2023 6 | 140 | 39 | 179 |
| 2023 5 | 149 | 35 | 184 |
| 2023 4 | 155 | 32 | 187 |
| 2023 3 | 130 | 31 | 161 |
| 2023 2 | 122 | 30 | 152 |
| 2023 1 | 76 | 28 | 104 |
| 2022 12 | 97 | 44 | 141 |
| 2022 11 | 61 | 43 | 104 |
| 2022 10 | 43 | 42 | 85 |
| 2022 9 | 61 | 32 | 93 |
| 2022 8 | 73 | 40 | 113 |
| 2022 7 | 51 | 55 | 106 |
| 2022 6 | 71 | 34 | 105 |
| 2022 5 | 189 | 40 | 229 |
| 2022 4 | 185 | 56 | 241 |
| 2022 3 | 178 | 74 | 252 |
| 2022 2 | 187 | 45 | 232 |
| 2022 1 | 238 | 58 | 296 |
| 2021 12 | 177 | 82 | 259 |
| 2021 11 | 182 | 59 | 241 |
| 2021 10 | 169 | 62 | 231 |
| 2021 9 | 182 | 56 | 238 |
| 2021 8 | 160 | 45 | 205 |
| 2021 7 | 138 | 65 | 203 |
| 2021 6 | 170 | 31 | 201 |
| 2021 5 | 358 | 34 | 392 |
| 2021 4 | 345 | 94 | 439 |
| 2021 3 | 252 | 40 | 292 |
| 2021 2 | 211 | 30 | 241 |
| 2021 1 | 149 | 30 | 179 |
| 2020 12 | 184 | 38 | 222 |
| 2020 11 | 116 | 21 | 137 |
| 2020 10 | 126 | 27 | 153 |
| 2020 9 | 94 | 21 | 115 |
| 2020 8 | 81 | 20 | 101 |
| 2020 7 | 79 | 11 | 90 |
| 2020 6 | 60 | 18 | 78 |
| 2020 5 | 50 | 25 | 75 |
| 2020 4 | 51 | 20 | 71 |
| 2020 3 | 32 | 15 | 47 |
| 2020 2 | 7 | 4 | 11 |
| 2020 1 | 7 | 1 | 8 |
| 2019 12 | 8 | 9 | 17 |
| 2019 11 | 4 | 11 | 15 |
| 2019 10 | 0 | 14 | 14 |
| 2019 9 | 5 | 13 | 18 |
| 2019 8 | 5 | 9 | 14 |
| 2019 7 | 6 | 22 | 28 |
| 2019 6 | 4 | 28 | 32 |
| 2019 5 | 7 | 102 | 109 |
| 2019 4 | 2 | 64 | 66 |
| 2019 3 | 4 | 25 | 29 |
| 2019 2 | 2 | 28 | 30 |
| 2019 1 | 5 | 21 | 26 |
| 2018 12 | 6 | 14 | 20 |
| 2018 11 | 0 | 9 | 9 |
| 2018 10 | 3 | 0 | 3 |
| 2018 9 | 4 | 26 | 30 |
| 2018 8 | 0 | 31 | 31 |
| 2018 7 | 1 | 30 | 31 |
| 2018 6 | 0 | 15 | 15 |
| 2018 5 | 0 | 17 | 17 |
| 2018 4 | 0 | 17 | 17 |
| 2018 3 | 8 | 17 | 25 |
| 2018 2 | 84 | 14 | 98 |
| 2018 1 | 85 | 19 | 104 |
| 2017 12 | 87 | 20 | 107 |
| 2017 11 | 59 | 37 | 96 |
| 2017 10 | 69 | 37 | 106 |
| 2017 9 | 53 | 18 | 71 |
| 2017 8 | 64 | 14 | 78 |
| 2017 7 | 62 | 21 | 83 |
| 2017 6 | 56 | 25 | 81 |
| 2017 5 | 57 | 28 | 85 |
| 2017 4 | 37 | 102 | 139 |
| 2017 3 | 32 | 77 | 109 |
| 2017 2 | 25 | 24 | 49 |
| 2017 1 | 21 | 19 | 40 |
| 2016 12 | 25 | 17 | 42 |
| 2016 11 | 35 | 35 | 70 |
| 2016 10 | 29 | 36 | 65 |
| 2016 9 | 0 | 22 | 22 |
| 2016 8 | 0 | 17 | 17 |
| 2016 7 | 9 | 3 | 12 |
| 2016 6 | 13 | 4 | 17 |
| 2016 5 | 20 | 4 | 24 |
| 2016 4 | 18 | 3 | 21 |
| 2016 3 | 21 | 4 | 25 |
| 2016 2 | 14 | 1 | 15 |
| 2016 1 | 9 | 2 | 11 |
| 2015 12 | 6 | 1 | 7 |
| 2015 11 | 7 | 4 | 11 |
| 2015 10 | 14 | 3 | 17 |
| 2015 9 | 10 | 3 | 13 |
| 2015 8 | 16 | 3 | 19 |
| 2015 7 | 97 | 10 | 107 |
| 2015 6 | 33 | 6 | 39 |
| 2015 5 | 14 | 6 | 20 |
| 2015 4 | 5 | 7 | 12 |
| 2015 3 | 13 | 1 | 14 |
| 2015 2 | 17 | 6 | 23 |
| 2015 1 | 5 | 5 | 10 |
| 2014 12 | 11 | 4 | 15 |
Show all
